Mirati Therapeutics (MRTX) Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRTX, but not buy additional shares or sell existing shares.
View MRTX analyst ratings or view top-rated stocks.

13 brokerages have issued 12-month price targets for Mirati Therapeutics' stock. Their MRTX share price forecasts range from $31.00 to $100.00. On average, they predict the company's share price to reach $63.08 in the next year. This suggests a possible upside of 70.5% from the stock's current price.
View analysts price targets for MRTX or view top-rated stocks among Wall Street analysts.

Mirati Therapeutics' stock was trading at $45.31 at the beginning of the year. Since then, MRTX stock has decreased by 18.3% and is now trading at $37.00.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our MRTX earnings forecast.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) released its earnings results on Tuesday, August, 8th. The biotechnology company reported ($3.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.23) by $0.19. The biotechnology company earned $13.70 million during the quarter, compared to analyst estimates of $13.17 million. Mirati Therapeutics had a negative net margin of 3,901.06% and a negative trailing twelve-month return on equity of 71.90%. The business's revenue for the quarter was up 153.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($3.18) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Candriam S.C.A. (1.50%), Assenagon Asset Management S.A. (1.39%), International Biotechnology Trust PLC (0.45%), Allspring Global Investments Holdings LLC (0.38%), Allspring Global Investments Holdings LLC (0.38%) and Bank of New York Mellon Corp (0.32%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, David D Meek, Henry J Fuchs, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Laurie Stelzer, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends.

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRTX stock can currently be purchased for approximately $37.00.

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.15 billion and generates $12.44 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($12.96) on an earnings per share basis.

The company employs 587 workers across the globe.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.